INmune Bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INmune Bio and other ETFs, options, and stocks.About INMB
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate.
CEODavid J. Moss
CEODavid J. Moss
Employees22
Employees22
HeadquartersBoca Raton, Florida
HeadquartersBoca Raton, Florida
Founded2015
Founded2015
Employees22
Employees22
INMB Key Statistics
Market cap49.13M
Market cap49.13M
Price-Earnings ratio-0.83
Price-Earnings ratio-0.83
Dividend yield—
Dividend yield—
Average volume374.60K
Average volume374.60K
High today$1.86
High today$1.86
Low today$1.70
Low today$1.70
Open price$1.72
Open price$1.72
Volume304.19K
Volume304.19K
52 Week high$11.64
52 Week high$11.64
52 Week low$1.38
52 Week low$1.38
Stock Snapshot
INmune Bio(INMB) stock is priced at $1.76, giving the company a market capitalization of 49.13M. It carries a P/E multiple of -0.83.
On 2025-12-25, INmune Bio(INMB) stock moved within a range of $1.70 to $1.86. With shares now at $1.76, the stock is trading +3.6% above its intraday low and -5.3% below the session's peak.
Trading volume for INmune Bio(INMB) stock has reached 304.19K, versus its average volume of 374.6K.
The stock's 52-week range extends from a low of $1.38 to a high of $11.64.
The stock's 52-week range extends from a low of $1.38 to a high of $11.64.
INMB News
TipRanks 2d
Inmune Bio Amends April 2024 Investor WarrantsClaim 70% Off TipRanks This Holiday Season An update from Inmune Bio ( (INMB) ) is now available. On December 22, 2025, INmune Bio Inc. amended certain invest...
People also own
Based on the portfolios of people who own INMB. This list is generated using Robinhood data, and it’s not a recommendation.